RNAC on Nasdaq

Selecta Biosciences (United States)

American pharmaceutical preparations company based in Watertown.¹

Price unavailable

Last updated Oct 18, 2026.

Overview

Jan 1, 2008Founded¹

Compare with Can Fite Biopharma, America Great Health or MEDICINOVA INC, or pick any stock.

TickerRNAC on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersWatertown¹
Websitewww.selectabio.com
Incorporated inDE³
Business address7495 New Horizon Way, Frederick, Md 21703³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-35851.2%Operating margin⁴

-32575.5%Net margin⁴

-99.0%Revenue growth, 2025⁴

-$79.4MFree cash flow⁴

Where the money goes

Where each dollar of revenue went, fiscal 2025

Research and developmentIncome tax

Research and development86¢$58.0M
Income tax14¢$9.2M

Out of $400.0K in revenue.⁴ The company lost money this year.

Financial statements

Revenue⁵⁶⁷⁸⁴$400.0K in 2025−94% since 2019

Operating income⁵⁶⁷⁸⁴-$143.4M in 2025+173% since 2019

Net income⁵⁶⁷⁸⁴-$130.3M in 2025+135% since 2019

Every line of the income statement in the latest annual report, as filed.⁴

Period ending	2025-12-31	2024-12-31
Collaboration and license	$400.0K	$38.3M
Grant	$2.4M	$638.0K
Total revenues	$2.8M	$38.9M
Research and development	$58.0M	$45.1M
General and administrative	$31.5M	$30.1M
Impairment of indefinite-lived intangible and long-lived assets	$56.7M	$7.6M
Total operating expenses	$146.2M	$82.8M
Operating loss	-$143.4M	-$43.9M
Interest income	$6.6M	$7.4M
Gain on change in fair value of warrant liabilities	$3.7M	$2.6M
Loss on change in fair value of contingent value right liability	-$4.4M	-$36.9M
Loss on change in fair value of forward contract liabilities	$0	-$6.9M
Other (expense) income, net	-$2.0M	$606.0K
Total other income (expense), net	$3.9M	-$33.2M
Loss before income taxes	-$139.5M	-$77.1M
Income tax benefit (expense)	$9.2M	-$287.0K
Net loss	-$130.3M	-$77.4M
Foreign currency translation adjustment	$45.0K	-$21.0K
Total comprehensive loss	-$130.3M	-$77.4M
Basic (in dollars per share)	-$5.02	-$4.48
Diluted (in dollars per share)	-$5.02	-$4.49
Basic (in shares)	26.0M shares	17.3M shares
Diluted (in shares)	26.0M shares	17.4M shares

Total assets¹¹⁵⁶⁷⁸⁴$296.4M in 2025+198% since 2019

Total liabilities¹¹⁵⁶⁷⁸⁴$422.7M in 2025+364% since 2019

Shareholders’ equity⁶⁷⁸⁴-$126.2M in 2025

Cash⁵⁶⁷⁸⁴$125.1M in 2025+39% since 2019

Every line of the balance sheet in the latest annual report, as filed.⁴

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$125.1M	$212.6M
Accounts receivable	$1.1M	$872.0K
Prepaid expenses and other current assets	$3.0M	$3.1M
Total current assets	$129.3M	$216.6M
Property and equipment, net	$12.2M	$9.9M
Right-of-use assets, net	$5.6M	$5.5M
In-process research and development assets	$93.9M	$150.6M
Goodwill	$48.2M	$48.2M
Long-term restricted cash	$1.7M	$1.7M
Investment	$0	$2.0M
Long-term prepaid expenses and other assets	$5.6M	$518.0K
Total assets	$296.4M	$435.0M
Accounts payable	$1.3M	$288.0K
Accrued expenses and other current liabilities	$9.5M	$12.1M
Lease liabilities	$4.2M	$2.9M
Contingent value right liability	$0	$7.8M
Total current liabilities	$14.9M	$23.0M
Lease liabilities, net of current portion	$8.5M	$11.1M
Warrant liability	$141.0K	$3.8M
Contingent value right liability, net of current portion	$392.1M	$387.7M
Deferred tax liabilities, net	$6.9M	$16.1M
Total liabilities	$422.7M	$441.8M
Preferred stock, value, issued	$0	$0
Common stock, $0.0001 par value; 350,000,000 shares authorized as of December 31, 2025 and 2024; 26,011,106 and 25,767,369 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$3.0K	$3.0K
Additional paid-in capital	$700.7M	$689.9M
Accumulated deficit	-$822.4M	-$692.1M
Accumulated other comprehensive loss	-$4.6M	-$4.6M
Total stockholders deficit	-$126.2M	-$6.8M	-$440.2M
Total liabilities and stockholders deficit	$296.4M	$435.0M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	9.4M shares
Preferred stock, shares issued (in shares)	0 shares	0 shares
Preferred stock, shares outstanding (in shares)	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	350.0M shares	350.0M shares
Common stock, shares issued (in shares)	26.0M shares	25.8M shares
Common stock, shares outstanding (in shares)	26.0M shares	25.8M shares

Cash from operations⁵⁶⁷⁸⁴-$73.9M in 2025+44% since 2019

Capital spending⁵⁶⁷⁸⁴$5.5M in 2025+11504% since 2019

Free cash flow⁵⁶⁷⁸⁴-$79.4M in 2025+54% since 2019

Every line of the cash flow in the latest annual report, as filed.⁴

Period ending	2025-12-31	2024-12-31
Net loss	-$130.3M	-$77.4M
Depreciation and amortization	$3.0M	$1.2M
Non-cash lease expense	$778.0K	$2.4M
Loss on disposal of property and equipment	$0	$273.0K
Impairment of indefinite-lived intangible and long-lived assets	$56.7M	$7.6M
Stock-based compensation expense	$10.5M	$6.6M
Gain on change in fair value of warrant liabilities	-$3.7M	-$2.6M
Loss on change in fair value of CVR liability	$4.4M	$36.9M
Loss on change in fair value of forward contract liabilities	$0	$6.9M
Loss on impairment of investment	$2.0M	$0
(Benefit) provision for deferred taxes	-$9.2M	$287.0K
Accounts receivable	-$243.0K	$5.0M
Unbilled receivable	$0	$3.0M
Prepaid expenses and other assets	-$5.3M	$1.7M
Accounts payable	$1.1M	-$2.9M
Deferred revenue	$0	-$5.8M
Accrued expenses and other liabilities	-$3.6M	-$6.7M
Net cash used in operating activities	-$73.9M	-$23.7M
Purchases of property and equipment	-$5.5M	-$9.1M
Proceeds from the sale of property and equipment	$0	$351.0K
Net cash used in investing activities	-$5.5M	-$8.7M
Proceeds from issuance of Series A Preferred Stock, gross in private placement	$0	$40.0M
Net proceeds from issuance of common stock and Series B Preferred Stock in private placement	$0	$124.4M
Equity offering costs	-$624.0K	-$66.0K
Proceeds from exercise of common warrants	$0	$2.9M
Proceeds from exercise of stock options	$323.0K	$1.2M
Distribution of Contingent Value Rights	-$7.8M	$0
Net cash (used in) provided by financing activities	-$8.1M	$168.4M
Effect of exchange rate changes on cash	$45.0K	-$21.0K
Net change in cash, cash equivalents, and restricted cash	-$87.4M	$136.0M
Purchase of property and equipment not yet paid	$18.0K	$847.0K
Equity offering costs in accrued liabilities	$30.0K	$451.0K
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	$844.0K	$5.2M

Compare Selecta Biosciences (United States) with another company

Leadership

Who has led Selecta Biosciences (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

2010201520202025

Chief executive officerCarsten Brunn Dec 3, 2018 to now¹²
Chief executive officerWerner Cautreels Jun 21, 2016 to Nov 14, 2017¹³
PresidentCarsten Brunn Dec 3, 2018 to now¹²
PresidentWerner Cautreels Jun 21, 2016 to Nov 14, 2017¹³
Chief financial officerBlaine Davis Nov 30, 2022 to now¹⁴
Chief financial officerKevin Tan Sep 22, 2021 to Jan 5, 2022¹⁵
Chief financial officerBradford D. Dahms Sep 5, 2019 to Jan 6, 2021¹⁶
Chief financial officerJohn Harold Leaman Oct 26, 2017 to Jun 19, 2018¹⁷
Chief financial officerDavid Siewers Jun 21, 2016 to Sep 22, 2017¹⁸
Chief operating officerMetin Kurtoglu Jan 4, 2024 to Jan 4, 2024¹⁹
Chief operating officerLloyd P. Johnston Jun 21, 2016 to Mar 19, 2021²⁰

Board members and other officers (34)

Chief Accounting OfficerJune Ann Seymour Oct 28, 2025 to now²¹
SVP, Head of ManufacturingEmily English Apr 19, 2024 to now²²
Chief Scientific OfficerChristopher M. Jewell Nov 15, 2023 to now²³
Chief Operations OfficerMetin Kurtoglu Nov 15, 2023 to now²⁴
Chief Medical OfficerMilos Miljkovic Nov 15, 2023 to now²⁵
Chief Operations OfficerLloyd P. Johnston Oct 5, 2021 to Jan 6, 2023²⁶
Chief Medical OfficerPeter G. Traber Aug 4, 2020 to Sep 26, 2023²⁷
ControllerAnn K. Donohue May 15, 2019 to Jun 3, 2021²⁸
Chief Medical OfficerAlison D. Schecter Jul 17, 2019 to Jan 6, 2020²⁹
Chief Commercial OfficerStephen Smolinski Oct 27, 2017 to Jan 6, 2020³⁰
Chief Medical OfficerEarl Sands Jun 21, 2016 to Nov 21, 2017³¹
Chief Scientific OfficerTakashi Kei Kishimoto Jun 21, 2016 to Jun 1, 2023³²
Board memberAdrian Ion Bot Dec 18, 2025 to now³³
Board memberKemal Malik Jul 3, 2024 to now³⁴
Board memberMurat Kalayoglu Nov 15, 2023 to now³⁵
Board memberNishan M. Desilva Jul 9, 2021 to now³⁶
Board memberGoran Ando Apr 28, 2020 to Jan 4, 2023³⁷
Board memberScott Dunseth Myers Jun 18, 2019 to Nov 15, 2023³⁸
Board memberCarrie Cox Nov 22, 2019 to now³⁹
Board memberCarsten Brunn Dec 3, 2018 to now¹²
Board memberPatrick J. Zenner Jun 20, 2017 to now⁴⁰
Board memberAmir Nashat Jun 21, 2016 to Jun 18, 2019⁴¹
Board memberAymeric Sallin Jun 21, 2016 to Jan 4, 2024⁴²
Board memberCarl L. Gordon Jun 21, 2016 to Jun 29, 2016⁴³
Board memberEdwin M. Kania Jr. Jun 21, 2016 to May 16, 2017⁴⁴
Board memberLeysan Shaydullina Jun 21, 2016 to Jun 21, 2016⁴⁵
Board memberNoubar Afeyan Jun 21, 2016 to Jun 21, 2016⁴⁴
Board memberOmid Cameron Farokhzad Jun 21, 2016 to Aug 16, 2019⁴⁶
Board memberPeter Barton Hutt Jun 21, 2016 to Jun 19, 2018⁴⁷
Board memberSamuel D. Isaly Jun 21, 2016 to Jun 29, 2016⁴⁸
Board memberTimothy A. Springer Jun 21, 2016 to now⁴⁹
Board memberWerner Cautreels Jun 21, 2016 to Nov 14, 2017¹³
Board memberTimothy C. Barabe Aug 2, 2016 to now⁵⁰
General counselElona Kogan Esq. Mar 27, 2019 to Jan 6, 2020⁵¹

Former names

SELECTA BIOSCIENCES INCJan 5, 2009 to Nov 13, 2023³

Timeline

Jul 2, 2024Funding Raised $130 million in a private offering of equity⁵²
Nov 13, 2023Funding Raised $60.2 million in a private offering of securities⁵³
Dec 3, 2018New chief executive Carsten Brunn becomes CEO¹²
Jun 21, 2016New chief executive Werner Cautreels becomes CEO¹³
Jan 1, 2008Founded Founded¹

Recent filings

Sep 29, 20268-K
Aug 13, 2026SCHEDULE 13G
Aug 6, 20268-K
Aug 6, 202610-Q
Jul 22, 2026SCHEDULE 13G/A
Jun 17, 20268-K
Jun 9, 20268-K
Jun 9, 2026144
Jun 2, 2026144
May 26, 20268-K
May 6, 2026SCHEDULE 13G/A
Apr 30, 20268-K
Apr 30, 202610-Q
Apr 30, 2026S-8
Apr 28, 2026DEFA14A

Every filing from the last three years, summarized. The full record is on SEC EDGAR.²

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataSelecta Biosciences (United States) on Wikidata
2
SEC EDGARSelecta Biosciences (United States) filings on SEC EDGAR
3
SEC EDGARSelecta Biosciences (United States) filings on SEC EDGAR
4
SEC EDGARSelecta Biosciences (United States) 10-K for fiscal 2025
5
SEC EDGARSelecta Biosciences (United States) 10-K for fiscal 2019
6
SEC EDGARSelecta Biosciences (United States) 10-K for fiscal 2020
7
SEC EDGARSelecta Biosciences (United States) 10-K for fiscal 2021
8
SEC EDGARSelecta Biosciences (United States) 10-K for fiscal 2023
9
SEC EDGARSelecta Biosciences (United States) 10-Q for fiscal 2026
10
SEC EDGARSelecta Biosciences (United States) 10-Q for fiscal 2026
11
SEC EDGARSelecta Biosciences (United States) 10-K for fiscal 2019
12
SEC EDGARCarsten Brunn, Chief executive officer
13
SEC EDGARWerner Cautreels, Chief executive officer
14
SEC EDGARBlaine Davis, Chief financial officer
15
SEC EDGARKevin Tan, Chief financial officer
16
SEC EDGARBradford D. Dahms, Chief financial officer
17
SEC EDGARJohn Harold Leaman, Chief financial officer
18
SEC EDGARDavid Siewers, Chief financial officer
19
SEC EDGARMetin Kurtoglu, Chief operating officer
20
SEC EDGARLloyd P. Johnston, Chief operating officer
21
SEC EDGARJune Ann Seymour, Chief Accounting Officer
22
SEC EDGAREmily English, SVP, Head of Manufacturing
23
SEC EDGARChristopher M. Jewell, Chief Scientific Officer
24
SEC EDGARMetin Kurtoglu, Chief Operations Officer
25
SEC EDGARMilos Miljkovic, Chief Medical Officer
26
SEC EDGARLloyd P. Johnston, Chief Operations Officer
27
SEC EDGARPeter G. Traber, Chief Medical Officer
28
SEC EDGARAnn K. Donohue, Controller
29
SEC EDGARAlison D. Schecter, Chief Medical Officer
30
SEC EDGARStephen Smolinski, Chief Commercial Officer
31
SEC EDGAREarl Sands, Chief Medical Officer
32
SEC EDGARTakashi Kei Kishimoto, Chief Scientific Officer
33
SEC EDGARAdrian Ion Bot, Board member
34
SEC EDGARKemal Malik, Board member
35
SEC EDGARMurat Kalayoglu, Board member
36
SEC EDGARNishan M. Desilva, Board member
37
SEC EDGARGoran Ando, Board member
38
SEC EDGARScott Dunseth Myers, Board member
39
SEC EDGARCarrie Cox, Board member
40
SEC EDGARPatrick J. Zenner, Board member
41
SEC EDGARAmir Nashat, Board member
42
SEC EDGARAymeric Sallin, Board member
43
SEC EDGARCarl L. Gordon, Board member
44
SEC EDGAREdwin M. Kania Jr., Board member
45
SEC EDGARLeysan Shaydullina, Board member
46
SEC EDGAROmid Cameron Farokhzad, Board member
47
SEC EDGARPeter Barton Hutt, Board member
48
SEC EDGARSamuel D. Isaly, Board member
49
SEC EDGARTimothy A. Springer, Board member
50
SEC EDGARTimothy C. Barabe, Board member
51
SEC EDGARElona Kogan Esq., General counsel
52
SEC EDGARRaised $130 million in a private offering of equity
53
SEC EDGARRaised $60.2 million in a private offering of securities